stay up to date on this topic
scientists have developed a therapy for lupus nephritis that targets specific immune cells and could be an alternative to current treatments.
researchers from the azrieli faculty of medicine of bar-ilan university, the albert einstein college of medicine, the university of houston, and the pharmaceutical company equillium produced the treatment. the discovery was published in the journal of clinical investigation.
lupus is an autoimmune disease that causes the body to attack itself. lupus nephritis, which affects about half of lupus patients, causes severe inflammation of the kidneys and can potentially result in irreparable damage.
the new treatment uses genes that produce proteins on the outer membrane of t cells, or white blood cells, which are essential for immune responses. dr. chaim putterman, of the azrieli faculty of medicine of bar-ilan university, says up until now, these genes were not considered relevant to lupus nephritis.
“the intervention we describe, which targets t cells rather than multiple immune cell types, can potentially provide physicians with another effective tool for treatment of a difficult and challenging disease,” putterman said in a statement.
researchers were able to develop an antibody that can disrupt the interaction between the potentially harmful immune cells, halting t cells from ever activating and resulting in a crucial decrease in kidney inflammation.
more than 1,000 people participated in the study, in which researchers monitored their urine for creatinine, a chemical compound that is left over when the body produces energy and is evacuated through urination. there are normal levels of creatinine a healthy person would produce, while lupus patients are found to have significantly higher levels.
medication options for lupus nephritis